Beta Bionics (BBNX) risk factors, FY2025 10-K

Risks Related to Our Limited Commercial History, Financial Position and Need for Additional Capital

1. 01We have a limited commercial history and limited experience marketing and selling our products. We only recently launched our commercial product, which may make it difficult to evaluate the prospects for our future viability and predict our future performance
2. 02We have incurred significant operating losses since inception and cannot assure you that we will be able to achieve or sustain profitability
3. 03Our quarterly and annual financial condition, operating results, cash flows and key business metrics may fluctuate in the future, which could cause the market price of our stock to decline substantially
4. 04general economic, political, industry and market conditions55% rewritten
5. 05fluctuates, our financial results may vary from period to period. Our ability to generate more revenue in the PBP channel over the patient’s lifespan will be dependent upon the continued use of our products by PWDNew
6. 06We currently rely on sales of our iLet and related single-use products to generate all of our revenue, and any factors that negatively impact sales of these products may adversely affect our business, financial condition and operating results
7. 07claims that any of our products, or any component thereof, infringes on patent rights or other intellectual property rights of third parties
8. 08We may need to raise additional funds in the future, and these funds may not be available on acceptable terms, if at all
9. 09the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims20% rewritten
10. 10Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or iLet

Risks Related to Our Business, Strategy and Industry

1. 11The failure of our iLet and related products to achieve and maintain market acceptance could result in us achieving sales below our expectations, which would cause our business, financial condition and operating results to be materially and adversely affected
2. 12results of clinical trials relating to our existing product or product candidates or to similar competitive products
3. 13The market opportunities for our iLet for the treatment of diabetes may be smaller than we anticipated, limiting our ability to successfully sell our current and future products
4. 14We face competition from numerous competitors, most of whom have far greater resources than we have, which may make it more difficult for us to achieve significant market penetration and which may allow them to develop additional products for the treatment of diabetes that compete with our iLet
5. 15Our results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory
6. 16Competing products, therapeutic techniques or other technological developments and breakthroughs for the monitoring, treatment or prevention of diabetes may render our products obsolete or less desirable
7. 17There can be no assurance that we will be able to successfully expand our distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or in other jurisdictions for which we are able to obtain regulatory clearance
8. 18We will need to expand our organization, and we may experience challenges in managing this growth as we build our capabilities, which could disrupt our operations
9. 19Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
10. 20We may acquire other companies or technologies, which could fail to result in a commercial product or revenue, divert our management’s attention, result in additional dilution to our stockholders and otherwise disrupt our business
11. 21If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our iLet and limit commercialization of any products that we may develop
12. 22termination of existing agreements by our partners and potential partners failing to partner with us
13. 23International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
14. 24Recent policy discussions have included potential targeted tariffs or other trade measures specifically aimed at medical device products and ingredients as part of broader healthcare cost control or national security initiativesNew
15. 25Risks Related to the Development, Regulatory Approval and Commercialization of our iLet Bionic Pancreas and Product Candidates
16. 26enforcing and defending intellectual property rights and claims85% rewritten
17. 27effectiveness of the device, we may need to make changes to or recall or withdraw the iLet from the field, which could harm our businessNew
18. 28the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval
19. 29Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Further, we may encounter substantial delays in our clinical trials
20. 30Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing authorization or clearance
21. 31lack of adequate funding to continue the clinical trial
22. 32Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
23. 33Unacceptable safety concerns caused by our commercial or development-stage products could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label, or the delay or denial of required marketing authorizations or clearances
24. 34we could face decreased demand for our products as a result of PWD, caregivers and HCPs losing confidence in our products
25. 35We are developing our iLet in combination with other therapies and devices, which requires additional development time and exposes us to additional risks52% rewritten
26. 36We have conducted, and may conduct additional, clinical trials for our glucagon product candidate outside the United States and the FDA may not accept data from such trialsNew
27. 37diminished protection of intellectual property in some countriesNew
28. 38Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed, authorized or commercialized in a timely manner, which could negatively impact our business
29. 39Our future growth depends on the continued success, enhancement, and expanded use of the iLet. If we fail to advance the iLet platform or expand its indications, our business may be adversely affectedNew
30. 40receive adequate coverage and reimbursement for procedures performed with the iLet
31. 41ability to achieve and maintain market share and increase our revenue, which could have a material adverse effect on our business, financial condition and results of operations

Risks Related to Reimbursement and Pricing

1. 42Coverage and reimbursement may be limited or unavailable in certain market segments for our iLet, which could make it difficult for us to sell any investigational devices profitably
2. 43neither experimental nor investigational
3. 44We are working with payors to establish coverage and reimbursement under both the DME and PBP channels as we believe that this strategy increases access and optimizes the potential for better medical outcomes for PWD through the adoption of the iLet
4. 45If we experience pricing pressure for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, financial condition, results of operations and cash flows
5. 46Healthcare reform measures could hinder or prevent the commercial success of our solutions49% rewritten
6. 47Uncertainty related to CMS reimbursement policies could adversely affect our pricing and revenueNew

Risks Related to Manufacturing and Our Reliance on Third Parties

1. 48collaboration agreements may restrict our right to independently pursue new investigational devices
2. 49We have limited experience manufacturing our products and, if we are unable to manufacture our products in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited
3. 50potential damage to or destruction of our manufacturing equipment or manufacturing facilities
4. 51We obtain some of the components and subassemblies included in our iLet from single source suppliers, and the partial or complete loss of one or more of these suppliers could cause significant production delays, an inability to meet customer demand and a substantial loss in revenue
5. 52we may not be able to quickly establish additional or replacement suppliers, particularly for our single source components
6. 53legal actions by our customers
7. 54Performance issues, service interruptions or price increases by our shipping carriers could negatively affect our business, financial condition and results of operations and harm our reputation and our customer relationships
8. 55We may enter into collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues
9. 56If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies
10. 57We rely and will continue to rely on third parties to conduct clinical trials of our iLet, which means we do not have full control over the conduct of such trials

Risks Related to Government Regulation

1. 58We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements31% rewritten
2. 59Our iLet or any of its components may be subject to product recalls in the future. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our iLet, could have a significant adverse impact on us21% rewritten
3. 60payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the False Claims ActNew
4. 61Additional federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers
5. 62The distribution of products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products
6. 63Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security96% rewritten
7. 64technical safeguards to protect such information, and certain notification requirements in the event of a breach of unsecured PHINew
8. 65Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR’s cross-border data transfer limitationsNew

Risks Related to Our Intellectual Property

1. 66If we are unable to obtain or protect intellectual property rights related to the iLet, we may not be able to compete effectively in our market73% rewritten
2. 67If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, we could lose rights, which may be important to our business
3. 68Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents
4. 69We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful
5. 70We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our product candidates
6. 71Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
7. 72The intellectual property or technology licensed from various third parties may be subject to retained rights
8. 73Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business
9. 74We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
10. 75We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property
11. 76We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
12. 77Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed to others
13. 78We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
14. 79Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
15. 80The terms of our patents may not be sufficiently long to effectively protect our products and business
16. 81If we are not successful in obtaining patent term extensions for our future products, our business may be harmed
17. 82Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business
18. 83Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Ownership of Our Common Stock

1. 84The trading price of our common stock may be volatile, and you could lose all or part of your investment
2. 85changes in accounting principles
3. 86Our executive officers, directors and principal stockholders, if they choose to act together, continue to have the ability to control or significantly influence all matters submitted to stockholders for approval
4. 87Future sales and issuances of our securities, including pursuant to our equity incentive plans, may cause dilution to our stockholders or decrease our stock price76% rewritten
5. 88We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
6. 89In addition, the JOBS Act allows us as an “emerging growth company” to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies
7. 90Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain
8. 91Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
9. 92provide that special meetings of our stockholders may be called only by the Chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors65% rewritten
10. 93could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transactionNew
11. 94Adverse changes in general economic conditions in the United States and outside of the United States could adversely affect us79% rewritten
12. 95financing of our operations, cause delays or other problems with key suppliers and increase the risk of counterparty failuresNew
13. 96Our ability to use our net operating loss (NOL) carryforwards and certain other tax attributes may be limited38% rewritten
14. 97We may be subject to adverse legislative or regulatory changes in tax laws, and there are uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations, any of which could materially affect our tax obligations and effective tax rate
15. 98We and our directors and executive officers may be subject to litigation for a variety of claims, which could harm our reputation and adversely affect our business, results of operations and financial condition
16. 99Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
17. 100We could be subject to securities class action litigation
18. 101If securities or industry analysts cease to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
19. 102Our insurance policies may be inadequate, may not cover all of our potential liabilities and may potentially expose us to unrecoverable risks
20. 103We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
21. 104Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (ESG) matters, may expose us to reputational and other risks
22. 105Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations